UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Volltextzugriff (PDF)

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers

Clinical cancer research, 2018-04, Vol.24 (8), p.1954-1964

2018

Volltextzugriff (PDF)

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

Journal of clinical oncology, 2016-03, Vol.34 (8), p.794-802

2016

Volltextzugriff (PDF)

AXL kinase as a novel target for cancer therapy

Oncotarget, 2014-10, Vol.5 (20), p.9546-9563

2014

Volltextzugriff (PDF)

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature reviews. Clinical oncology, 2021-05, Vol.18 (5), p.313-319

2021

Volltextzugriff (PDF)

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

Clinical cancer research, 2017-02, Vol.23 (3), p.825-832

2017

Volltextzugriff (PDF)

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

Science translational medicine, 2012-02, Vol.4 (120), p.120ra17

2012

Volltextzugriff (PDF)

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1742-1751

2008

Volltextzugriff (PDF)

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Nature genetics, 2012-08, Vol.44 (8), p.852-860

2012

Volltextzugriff (PDF)

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

Journal of clinical oncology, 2009-02, Vol.27 (4), p.619-628

2009

Volltextzugriff (PDF)

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

Journal of thoracic oncology, 2017-06, Vol.12 (6), p.932-942

2017

Volltextzugriff (PDF)

Real-world outcomes on platinum-containing chemotherapy for EGFR -mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

Frontiers in oncology, 2024-04, Vol.14, p.1285280-1285280

2024

Volltextzugriff (PDF)

VEGF inhibitors in EGFR -mutated lung cancer: a never-ending story?

Annals of translational medicine, 2018-12, Vol.6 (23), p.446-446

2018

Volltextzugriff (PDF)

Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer

Targeted oncology, 2022-03, Vol.17 (2), p.187-192

2022

Volltextzugriff (PDF)

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Oncotarget, 2016-05, Vol.7 (20), p.28976-28988

2016

Volltextzugriff (PDF)

Continuous Activity Monitoring during Concurrent Chemoradiotherapy

International journal of radiation oncology, biology, physics, 2017-04, Vol.97 (5), p.1061-1065

2017

Volltextzugriff (PDF)

FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis

Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2023-08, Vol.11 (4), p.381-387

2023

Volltextzugriff (PDF)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis

Translational lung cancer research, 2022-02, Vol.11 (2), p.277-294

2022

Volltextzugriff (PDF)

EGFR-mutated lung cancer: a paradigm of molecular oncology

Oncotarget, 2010-11, Vol.1 (7), p.497-514

2010

Volltextzugriff (PDF)

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery

Pathology oncology research, 2024-06, Vol.30, p.1611817

2024

Volltextzugriff (PDF)

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

Carcinogenesis (New York), 2010-04, Vol.31 (4), p.577-586

2010

Volltextzugriff (PDF)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC

Cancers, 2020-12, Vol.12 (12), p.3648

2020

Volltextzugriff (PDF)

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Clinical cancer research, 2009-05, Vol.15 (10), p.3484-3494

2009

Volltextzugriff (PDF)

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1

PloS one, 2014-09, Vol.9 (9), p.e106349

2014

Volltextzugriff (PDF)

Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer

Scientific reports, 2022-06, Vol.12 (1), p.10140-10140, Article 10140

2022

Volltextzugriff (PDF)

1 – 25 von 391

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(343)
Mit Volltextzugriff
(329)

Publikationsform

Sprache

Englisch
(383)
Japanisch
(36)
Ungarisch
(4)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(205)
Life Sciences & Biomedicine
(201)
Oncology
(151)
Humans
(133)
Lung Cancer
(66)
Male
(58)
Lung Neoplasms - Drug Therapy
(52)
Female
(51)
Middle Aged
(48)
Lung Neoplasms - Genetics
(45)
Mutation
(45)
Tumors
(45)
Aged
(43)
Biological And Medical Sciences
(42)
Lung Neoplasms - Pathology
(41)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(39)
Chemotherapy
(39)
Respiratory System
(39)
Medical Sciences
(38)
Adult
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

AXL kinase as a novel target for cancer therapy

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

Real-world outcomes on platinum-containing chemotherapy for EGFR -mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

VEGF inhibitors in EGFR -mutated lung cancer: a never-ending story?

Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Continuous Activity Monitoring during Concurrent Chemoradiotherapy

FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis

EGFR-mutated lung cancer: a paradigm of molecular oncology

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1

Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer

Suchergebnisse filtern